Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients | Zendy

CK Anulekha Avinash | Zendy; ML Avinash Tejasvi | Zendy; G Maragathavalli | Zendy; P. Udaykumar | Zendy; Manasa Ramakrishna | Zendy; R. Vijayaraghavan | Zendy

Open Access

Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients

Author(s) -

CK Anulekha Avinash,

ML Avinash Tejasvi,

G Maragathavalli,

P. Udaykumar,

Manasa Ramakrishna,

R. Vijayaraghavan

Publication year - 2020

Publication title -

indian journal of pathology and microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.217

H-Index - 31

eISSN - 0974-5130

pISSN - 0377-4929

DOI - 10.4103/ijpm.ijpm_964_19

Subject(s) - ercc1 , nucleotide excision repair , cisplatin , genotype , dna repair , oncology , single nucleotide polymorphism , cancer research , medicine , chemotherapy , gene , basal cell , biology , genetics

Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment. The aim of this study was to investigate the association between polymorphisms in ERCC1 (C118T & C8092A) genes and the response to cisplatin-based chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research